Hims & Hers health CEO Dudum sells $2.5m in shares

Hims & Hers Health, Inc. (NYSE:HIMS) Chief Executive Officer Andrew Dudum sold a total of 49,826 shares of Class A Common Stock on July 16, 2025, for approximately $2.5 million. The sales were executed in three separate transactions with prices ranging from $50.237 to $50.8213.

According to a Form 4 filing with the Securities and Exchange Commission, Dudum sold 2,792 shares directly at an average price of $50.579, with individual prices ranging from $50.47 to $50.745.

Additionally, Dudum, as trustee of the Dudum Family Community Property Trust, indirectly sold 1,458 shares at an average price of $50.8213, with prices ranging from $50.79 to $50.89, and 46,076 shares at an average price of $50.237, with prices ranging from $49.80 to $50.785.

Following these transactions, Dudum directly owns 92,313 shares of HIMS, while the Dudum Family Community Property Trust holds 426,328 shares.

The sales were conducted under a Rule 10b5-1 trading plan adopted by Dudum on August 28, 2024.

In other recent news, Hims & Hers has been navigating a series of developments impacting its operations and future strategies. The company recently faced a significant shift as Novo Nordisk (NYSE:NVO) terminated their partnership, accusing Hims & Hers of selling compounded versions of Wegovy and engaging in deceptive marketing practices. This has led to potential legal challenges, including a class action lawsuit against Hims & Hers. Amid these challenges, the company announced plans to expand into Canada in 2026, offering generic semaglutide following Novo Nordisk’s patent expiration in the region. This move is part of Hims & Hers’ broader international growth strategy, which includes a recent acquisition of Zava.

Analysts have weighed in on these developments, with BofA Securities maintaining an Underperform rating and highlighting mixed catalysts for growth, while Morgan Stanley (NYSE:MS) reiterated an Equalweight rating, noting slowing business momentum. Citi, on the other hand, has reiterated its Sell rating, commenting on the limited pricing arbitrage opportunity in the Canadian market. Hims & Hers continues to make strategic moves, such as increasing marketing for GLP-1s and planning geographic expansions, which analysts suggest may improve growth trajectory in the coming years. Despite the challenges, the company remains focused on leveraging its marketing capabilities to attract new customers and expand its reach.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.